Kura Oncology (KURA) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Kura Oncology Reports Second Quarter 2023 Financial Results
August 3, 2023 4:05 PM EDTEnrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections
First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML
Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA
Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC
First-in-human study of next-generation FTI KO-2806 to begin in second half of 2023
$477 million in cash, equivalents and investments provide runway to mid-2026
Management to host webcast and... More
